参一胶囊在晚期非小细胞肺癌维持治疗中的效果观察

Abstract
Figure/Table
References (16)
Related Citation (15)

Download: PDF (0 KB) HTML (41 KB)
Export: BibTeX | EndNote (RIS)

Abstract ObjectiveTo invesigate the effect of Shenyi Capsules for advanced non-small cell lung cancer(NSCLC) maintenance treatment.MethodsFrom July 2013 to October 2015,90 cases of advanced NSCLC patients with stage Ⅲb~Ⅳ were divided into control group and study group according to the random number table method,45 cases in each group.Control group was treated with pemetrexed,study group was treated with Shenyi Capsules.Patients of the two groups were treated for four cycles.The rate of total effective,rate of treatment benefit,KPS score,and immune function indexes such as CD3+,CD4+,CD8+,CD4+/CD8+of the two groups before and after treatmentwere compared;the adverse reactions of the two groupswere compared.ResultsThe total effective rate of the study group was 53.33%,and the rate of therapeutic benefitwas 84.44%,which were significantly higher than those of the control group (31.11%,66.67%),the differenceswere statistically significant(P<0.05).After treatment,the total increase rate of KPS score in the study group was significantly higher than that of the control group,and the immune function indexes of the two groups were significantly lower than those before treatment,and study group was higher than those of the control group,the differenceswere statistically significant(P<0.05);there was no serious adverse reactions in two groups.ConclusionShenyi Capsules maintenance treatment can significantly improve the efficiency,the quality of life and immune function of patients with advanced NSCLC,so it isworthy of clinical application.

Key words： Shenyi capsules Advanced Non small cell lung cancer Maintenance treatment Effect

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	LIU Zun-tao
	LIHong-yan

Cite this article:

LIU Zun-tao,LIHong-yan. Effect observation of Shenyi Capsules in the maintenance treatment of advanced non-small cell lung cancer[J]. 中国当代医药, 2016, 23(33): 85-87转97.

URL:

http://dangdaiyiyao.com/EN/ OR http://dangdaiyiyao.com/EN/Y2016/V23/I33/85

[3]	于飞，刘晓晴，李晓燕，等.培美曲塞单药或联合铂类三线及以上治疗晚期非鳞型非小细胞肺癌的临床观察[J].中国肺癌杂志，2012，15（2）：117-121.
[4]	马少军，张洁，单丽珠，等.参一胶囊联合化疗对胰腺癌患者外周血细胞水平及免疫细胞活性的影响[J].中国中西医结合外科杂志，2012，18（2）：134-136.
[5]	游捷，单孟俊，赵慧，等.中西医结合治疗91例老年晚期非小细胞肺癌疗效观察[J].中国中西医结合杂志，2012，32（6）：774-778.
[6]	石远凯，郏博.晚期非小细胞肺癌治疗的新趋势[J].中国新药杂志，2012，21（17）：1985-1991.
[1]	陈红涛，宋小花，肖桂英，等.吉非替尼治疗晚期非小细胞肺癌的不良反应及护理进展[J].护士进修杂志，2012，27 （4）：302-304.
[2]	丁春杰，杨磊.参芪扶正注射液对晚期非小细胞肺癌化疗患者免疫功能的影响[J].西部中医药，2012，25（1）：7-9.
[7]	胡兴胜，焦顺昌，张树才，等.培美曲塞及吉西他滨分别联合顺铂治疗初治晚期非小细胞肺癌安全性和有效性的随机对照研究[J].中国肺癌杂志，2012，15（10）：569-575.
[8]	周斌，单泽松，方媚媚，等.六君子汤加减辅助化疗治疗晚期非小细胞肺癌31例临床观察[J].中医杂志，2015，56（3）：219-222.
[9]	宋勇，杨雯.2014年晚期非小细胞肺癌内科治疗进展[J].解放军医学杂志，2015，40（1）：10-15.
[10]	过为，李健华，王峰.奈达铂联合化疗治疗晚期非小细胞肺癌疗效和安全性的Meta分析[J].中国循证医学杂志，2013，13（1）：47-54.
[11]	郑积华，林金容，谢波，等.培美曲塞与多西他赛二线随机分组治疗晚期非小细胞肺癌对比分析[J].中华肿瘤防治杂志，2013，20（5）：368-370.
[12]	蔡俊霞，谭洁，王彬，等.DC-CIK治疗43例晚期非小细胞肺癌的近期疗效观察[J].现代肿瘤医学，2014，22（1）：67-70.
[13]	廉政君，黄建国.晚期非小细胞肺癌预后相关因素分析[J].现代肿瘤医学，2014，22（1）：95-97.
[14]	刘苓霜，沈丽萍，姜怡，等.中医综合方案维持疗法对晚期非小细胞肺癌患者生存期的影响[J].中国中西医结合杂志，2014，34（5）：526-530.
[15]	成远，陈超，陈歆妮，等.参一胶囊对恶性肿瘤患者血清血管内皮生长因子影响的Meta分析[J].现代肿瘤医学，2015，23（6）：844-849.
[16]	方珊珊，戈伟，宋婧，等.Rg3联合化疗对中晚期非小细胞肺癌临床疗效及安全性的系统评价[J].中国医药导报，2015，12（35）：87-92.